Cargando…

A novel quantification method of lung fibrosis based on Micro-CT images developed with the optimized pulmonary fibrosis mice model induced by bleomycin

BACKGROUND AND AIMS: Idiopathic pulmonary fibrosis (IPF) is a fibrosing lung disease with unknown etiology, leading to cough and dyspnoea, which is also one of the most common sequelae affecting the quality of life of COVID-19 survivors. There is no cure for IPF patients. We aim to develop a reliabl...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Xi, Huang, Xue-Jun, Chen, Zhang, Xu, Ai-Li, Zhou, Hua, Bi, Xiao-Li, Yan, Pei-Yu, Xie, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988492/
https://www.ncbi.nlm.nih.gov/pubmed/36895392
http://dx.doi.org/10.1016/j.heliyon.2023.e13598
_version_ 1784901583893430272
author Yang, Xi
Huang, Xue-Jun
Chen, Zhang
Xu, Ai-Li
Zhou, Hua
Bi, Xiao-Li
Yan, Pei-Yu
Xie, Ying
author_facet Yang, Xi
Huang, Xue-Jun
Chen, Zhang
Xu, Ai-Li
Zhou, Hua
Bi, Xiao-Li
Yan, Pei-Yu
Xie, Ying
author_sort Yang, Xi
collection PubMed
description BACKGROUND AND AIMS: Idiopathic pulmonary fibrosis (IPF) is a fibrosing lung disease with unknown etiology, leading to cough and dyspnoea, which is also one of the most common sequelae affecting the quality of life of COVID-19 survivors. There is no cure for IPF patients. We aim to develop a reliable IPF animal model with quantification of fibrosis based on Micro-Computer Tomography (micro-CT) images for the new drug discovery, because different bleomycin administration routes, doses, and intervals are reported in the literature, and there is no quantitative assessment of pulmonary fibrosis based on micro-CT images in animal studies. METHODS: We compared three dosages (1.25 mg/kg, 2.5 mg/kg, and 5 mg/kg) of intratracheal bleomycin administration and experiment intervals (14 and 21 days) in C57BL/6 mice by investigating survival rates, pulmonary histopathology, micro-CT, peripheral CD4(+) & CD8(+) cells, and cytokines. Moreover, a simple and reliable new method was developed for scoring fibrosis in live mice based on Micro-CT images by using Image J software, which transfers the dark sections in pulmonary Micro-CT images to light colors on a black background. RESULTS: The levels of hydroxyproline, inflammation cytokine, fibrotic pathological changes, and collagen deposition in the lungs of mice were bleomycin dose-dependent and time-dependent as well as the body weight loss. Based on the above results, the mice model at 21 days after being given bleomycin at 1.25 mg/kg has optimal pulmonary fibrosis with a high survival rate and low toxicity. There is a significant decrease in the light area (gray value at 9.86 ± 0.72) in the BLM mice, indicating that a significant decrease in the alveolar air area was observed in BLM injured mice compared to normal groups (###p < 0.001), while the Pirfenidone administration increased the light area (gray value) to 21.71 ± 2.95 which is close to the value observed in the normal mice (gray value at 23.23 ± 1.66), which is consistent with the protein levels of Col1A1, and α-SMA. Notably, the standard deviations for the consecutive six images of each group indicate the precision of this developed quantitation method for the micro-CT image taken at the fifth rib of each mouse. CONCLUSION: Provided a quantifying method for Micro-CT images in an optimal and repeatable pulmonary fibrosis mice model for exploring novel therapeutic interventions.
format Online
Article
Text
id pubmed-9988492
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-99884922023-03-08 A novel quantification method of lung fibrosis based on Micro-CT images developed with the optimized pulmonary fibrosis mice model induced by bleomycin Yang, Xi Huang, Xue-Jun Chen, Zhang Xu, Ai-Li Zhou, Hua Bi, Xiao-Li Yan, Pei-Yu Xie, Ying Heliyon Research Article BACKGROUND AND AIMS: Idiopathic pulmonary fibrosis (IPF) is a fibrosing lung disease with unknown etiology, leading to cough and dyspnoea, which is also one of the most common sequelae affecting the quality of life of COVID-19 survivors. There is no cure for IPF patients. We aim to develop a reliable IPF animal model with quantification of fibrosis based on Micro-Computer Tomography (micro-CT) images for the new drug discovery, because different bleomycin administration routes, doses, and intervals are reported in the literature, and there is no quantitative assessment of pulmonary fibrosis based on micro-CT images in animal studies. METHODS: We compared three dosages (1.25 mg/kg, 2.5 mg/kg, and 5 mg/kg) of intratracheal bleomycin administration and experiment intervals (14 and 21 days) in C57BL/6 mice by investigating survival rates, pulmonary histopathology, micro-CT, peripheral CD4(+) & CD8(+) cells, and cytokines. Moreover, a simple and reliable new method was developed for scoring fibrosis in live mice based on Micro-CT images by using Image J software, which transfers the dark sections in pulmonary Micro-CT images to light colors on a black background. RESULTS: The levels of hydroxyproline, inflammation cytokine, fibrotic pathological changes, and collagen deposition in the lungs of mice were bleomycin dose-dependent and time-dependent as well as the body weight loss. Based on the above results, the mice model at 21 days after being given bleomycin at 1.25 mg/kg has optimal pulmonary fibrosis with a high survival rate and low toxicity. There is a significant decrease in the light area (gray value at 9.86 ± 0.72) in the BLM mice, indicating that a significant decrease in the alveolar air area was observed in BLM injured mice compared to normal groups (###p < 0.001), while the Pirfenidone administration increased the light area (gray value) to 21.71 ± 2.95 which is close to the value observed in the normal mice (gray value at 23.23 ± 1.66), which is consistent with the protein levels of Col1A1, and α-SMA. Notably, the standard deviations for the consecutive six images of each group indicate the precision of this developed quantitation method for the micro-CT image taken at the fifth rib of each mouse. CONCLUSION: Provided a quantifying method for Micro-CT images in an optimal and repeatable pulmonary fibrosis mice model for exploring novel therapeutic interventions. Elsevier 2023-02-10 /pmc/articles/PMC9988492/ /pubmed/36895392 http://dx.doi.org/10.1016/j.heliyon.2023.e13598 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Yang, Xi
Huang, Xue-Jun
Chen, Zhang
Xu, Ai-Li
Zhou, Hua
Bi, Xiao-Li
Yan, Pei-Yu
Xie, Ying
A novel quantification method of lung fibrosis based on Micro-CT images developed with the optimized pulmonary fibrosis mice model induced by bleomycin
title A novel quantification method of lung fibrosis based on Micro-CT images developed with the optimized pulmonary fibrosis mice model induced by bleomycin
title_full A novel quantification method of lung fibrosis based on Micro-CT images developed with the optimized pulmonary fibrosis mice model induced by bleomycin
title_fullStr A novel quantification method of lung fibrosis based on Micro-CT images developed with the optimized pulmonary fibrosis mice model induced by bleomycin
title_full_unstemmed A novel quantification method of lung fibrosis based on Micro-CT images developed with the optimized pulmonary fibrosis mice model induced by bleomycin
title_short A novel quantification method of lung fibrosis based on Micro-CT images developed with the optimized pulmonary fibrosis mice model induced by bleomycin
title_sort novel quantification method of lung fibrosis based on micro-ct images developed with the optimized pulmonary fibrosis mice model induced by bleomycin
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988492/
https://www.ncbi.nlm.nih.gov/pubmed/36895392
http://dx.doi.org/10.1016/j.heliyon.2023.e13598
work_keys_str_mv AT yangxi anovelquantificationmethodoflungfibrosisbasedonmicroctimagesdevelopedwiththeoptimizedpulmonaryfibrosismicemodelinducedbybleomycin
AT huangxuejun anovelquantificationmethodoflungfibrosisbasedonmicroctimagesdevelopedwiththeoptimizedpulmonaryfibrosismicemodelinducedbybleomycin
AT chenzhang anovelquantificationmethodoflungfibrosisbasedonmicroctimagesdevelopedwiththeoptimizedpulmonaryfibrosismicemodelinducedbybleomycin
AT xuaili anovelquantificationmethodoflungfibrosisbasedonmicroctimagesdevelopedwiththeoptimizedpulmonaryfibrosismicemodelinducedbybleomycin
AT zhouhua anovelquantificationmethodoflungfibrosisbasedonmicroctimagesdevelopedwiththeoptimizedpulmonaryfibrosismicemodelinducedbybleomycin
AT bixiaoli anovelquantificationmethodoflungfibrosisbasedonmicroctimagesdevelopedwiththeoptimizedpulmonaryfibrosismicemodelinducedbybleomycin
AT yanpeiyu anovelquantificationmethodoflungfibrosisbasedonmicroctimagesdevelopedwiththeoptimizedpulmonaryfibrosismicemodelinducedbybleomycin
AT xieying anovelquantificationmethodoflungfibrosisbasedonmicroctimagesdevelopedwiththeoptimizedpulmonaryfibrosismicemodelinducedbybleomycin
AT yangxi novelquantificationmethodoflungfibrosisbasedonmicroctimagesdevelopedwiththeoptimizedpulmonaryfibrosismicemodelinducedbybleomycin
AT huangxuejun novelquantificationmethodoflungfibrosisbasedonmicroctimagesdevelopedwiththeoptimizedpulmonaryfibrosismicemodelinducedbybleomycin
AT chenzhang novelquantificationmethodoflungfibrosisbasedonmicroctimagesdevelopedwiththeoptimizedpulmonaryfibrosismicemodelinducedbybleomycin
AT xuaili novelquantificationmethodoflungfibrosisbasedonmicroctimagesdevelopedwiththeoptimizedpulmonaryfibrosismicemodelinducedbybleomycin
AT zhouhua novelquantificationmethodoflungfibrosisbasedonmicroctimagesdevelopedwiththeoptimizedpulmonaryfibrosismicemodelinducedbybleomycin
AT bixiaoli novelquantificationmethodoflungfibrosisbasedonmicroctimagesdevelopedwiththeoptimizedpulmonaryfibrosismicemodelinducedbybleomycin
AT yanpeiyu novelquantificationmethodoflungfibrosisbasedonmicroctimagesdevelopedwiththeoptimizedpulmonaryfibrosismicemodelinducedbybleomycin
AT xieying novelquantificationmethodoflungfibrosisbasedonmicroctimagesdevelopedwiththeoptimizedpulmonaryfibrosismicemodelinducedbybleomycin